GSK

GlaxoSmithKline (GSK) has faced significant regulatory actions from South Korea's Ministry of Food and Drug Safety (MFDS), which issued two administrative penalties. The penalties...

GSK plc and Flagship Pioneering, a bioplatform innovation company, have announced a groundbreaking collaboration aimed at discovering and developing a portfolio of future transformational...

GSK plc announced the presentation of four new abstracts about dementia and Alzheimer's disease at the Alzheimer’s Association International Conference (AAIC). These presentations mark...

GSK plc announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel (chemotherapy) followed by...

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, has announced positive in vitro findings for its...

Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract disease (LRTD) in adults, particularly those with underlying health conditions. GSK has...

Antiviral activity against integrase resistance has been demonstrated by ViiV Healthcare’s investigational third-generation integrase inhibitor, VH4524184 (VH184). Data from this promising research, along with...

Pregnancy safety and health outcomes for women using Apretude (cabotegravir long-acting for PrEP) have been a focus of recent studies, with positive findings announced...

AIDS 2024 will feature significant findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study, which evaluates the treatment efficacy, safety, and weight changes experienced by...

The new licensing agreement with CureVac grants GlaxoSmithKline (GSK) global rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19, including...

Respiratory syncytial virus (RSV) immunization recommendations have been updated by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices...

Endometrial cancer treatment options may expand as the European Medicines Agency (EMA) has accepted GlaxoSmithKline's (GSK) application to use Jemperli (dostarlimab) in combination with...

GlaxoSmithKline (GSK) has entered into a $37.5 million partnership with Ochre Bio to leverage artificial intelligence (AI) and advanced biological platforms to pinpoint the...

Respiratory syncytial virus (RSV) vaccine, adjuvanted, developed by GSK, has received approval from the U.S. Food and Drug Administration (FDA) for use in adults...

The U.S. Food and Drug Administration (FDA) has granted priority review to GlaxoSmithKline's (GSK) supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) used in...